KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Idexx Laboratories (IDXX) over the last 16 years, with Sep 2025 value amounting to $36.6 million.

  • Idexx Laboratories' Depreciation & Amortization (CF) rose 7.31% to $36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.2 million, marking a year-over-year increase of 11.27%. This contributed to the annual value of $129.9 million for FY2024, which is 13.08% up from last year.
  • According to the latest figures from Q3 2025, Idexx Laboratories' Depreciation & Amortization (CF) is $36.6 million, which was up 2.39% from $35.8 million recorded in Q2 2025.
  • In the past 5 years, Idexx Laboratories' Depreciation & Amortization (CF) registered a high of $36.6 million during Q3 2025, and its lowest value of $25.1 million during Q1 2021.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $32.2 million (2024), whereas its average is $31.9 million.
  • In the last 5 years, Idexx Laboratories' Depreciation & Amortization (CF) declined by 0.95% in 2023 and then grew by 17.76% in 2024.
  • Idexx Laboratories' Depreciation & Amortization (CF) (Quarterly) stood at $27.7 million in 2021, then grew by 3.70% to $28.7 million in 2022, then climbed by 3.54% to $29.7 million in 2023, then grew by 13.35% to $33.7 million in 2024, then rose by 7.31% to $36.6 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $36.6 million for Q3 2025, versus $35.8 million for Q2 2025 and $34.1 million for Q1 2025.